-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SARS-CoV
CAS No. | Product Name | Inquiry |
---|---|---|
2599039-61-7 |
Crexavibart |
|
2640223-84-1 |
Masavibart |
|
2640224-48-0 |
Nepuvibart |
|
2641299-75-2 |
RdRP-IN-3RdRP-IN-3 is a small molecule inhibitor targeting the RNA-dependent RNA polymerase (RdRP) enzyme, which is essential for the replication of RNA viruses. By inhibiting RdRP, RdRP-IN-3 disrupts the viral replication process, potentially reducing the viral load and alleviating the severity of infections caused by RNA viruses. This makes RdRP-IN-3 a candidate for antiviral therapy against diseases caused by such viruses, offering a strategic approach to managing viral infections and improving treatment outcomes. |
|
2647441-36-7 |
ObeldesivirObeldesivir is an oral prodrug of the parent nucleoside GS-441524, which targets the highly conserved RNA-dependent viral RNA polymerase (RdRp). |
|
2647442-13-3 |
GS-621763GS-621763 is an orally bioavailable prodrug of GS-441524. The nucleoside metabolite of remdesivir, GS-441524 displays potent anti-SARS-CoV-2 efficacy, and is being evaluated in clinical as an oral antiviral therapeutic for COVID-19. |
|
2647530-73-0 |
EnsitrelvirEnsitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM). |
|
2648089-95-4 |
AT-9010 triethylamineThe active triphosphate metabolite AT-9010 can inhibit SARS-CoV-2 replication. |
|
2657659-42-0 |
Jun9-72-2 |
|
2679814-93-6 |
SARS-CoV-2 Mpro-IN-14 |
|
2682897-84-1 |
SARS-CoV-2-IN-68 |
|
2698336-82-0 |
Antiviral agent 5An intermediate in the numerous antiviral protease inhibitors is the glutamine analogue. Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 Mpro. |
|
2708270-99-7 |
SIMR3030 |
|
2708934-53-4 |
CCF0058981CCF0058981, a non-covalent SARS-CoV-2 3CLpro (SC2) inhibitor (IC50 = 68 nM), can inhibit SARS-CoV-1 3CLpro (SC1) with an IC50 of 19 nM. It has antiviral efficacy and has the potential to study COVID-19. |
|
2710278-53-6 |
SARS-CoV-2-IN-22SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals. |
|
2712126-48-0 |
Imiquimod-d9Imiquimod-d9 (R 837-d9) is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19. |
|
2713437-86-4 |
Pomotrelvir |
|
2719679-31-7 |
MMT5-14MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). |
|
2721455-52-1 |
SARS-CoV-2-IN-12SARS-CoV-2-IN-12 (Compound 27) is a potent SARS-CoV-2-related 3C-like protease inhibitor (Ki=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals. |
|
2722634-95-7 |
SARS-CoV-2-IN-10SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication. SARS-CoV-2-IN-10 may be a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease. |
※ Please kindly note that our services are for research use only.